Protea Biosciences 10-Q 9 May 14 2014 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2014	9-May-14
Document Information [Line Items]	'	'
Entity Registrant Name	'Protea Biosciences Group, Inc.	'
Entity Central Index Key	'0001335103	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'PTBG	'
Entity Common Stock, Shares Outstanding	'	65,705,083
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$313,286	$1,086,330
Trade accounts receivable	115,346	216,864
Other receivables	436,871	435,278
Inventory	553,363	465,334
Prepaid expenses	134,622	304,696
Total current assets	1,553,488	2,508,502
Property and equipment, net	3,324,753	2,886,176
Other noncurrent assets	23,231	23,249
Total Assets	4,901,472	5,417,927
Current Liabilities:	'	'
Current maturities on short and long-term debt	1,221,218	1,054,053
Accounts payable	1,671,512	759,021
Bank line of credit	3,000,000	2,725,000
Loans payable to stockholders, net of discount	1,070,883	465,883
Obligation related to the letter of credit, net of discount	69,827	151,981
Other payables and accrued expenses	862,500	1,069,167
Total current liabilities	7,895,940	6,225,105
Option fee	300,000	0
Long-term debt - net of current portion	1,754,296	1,580,260
Derivative Liabilities	557,665	623,587
Noncurrent Liabilities	2,311,961	2,203,847
Commitments and contingencies	'	'
Stockholders' Equity:	'	'
Preferred stock ($.0001 par value; 10,000,000 shares authorized; none issued or outstanding)	0	0
Common stock ($.0001 par value; 200,000,000 shares authorized; 65,467,735 and 65,442,735 shares issued and outstanding at March 31, 2014 and December 31, 2013)	6,547	6,545
Additional paid in capital	55,487,576	55,351,613
Deficit accumulated during development stage	-61,124,486	-58,392,348
Accumulated other comprehensive income (loss)	23,934	23,165
Total Stockholders' Equity (Deficit)	-5,606,429	-3,011,025
Total Liabilities and Stockholders' Equity	$4,901,472	$5,417,927

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	65,467,735	65,442,735
Common stock, shares outstanding	65,467,735	65,442,735

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		153 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Gross revenue	$468,100	$481,615	$5,184,447
Selling, general, administrative expenses	-2,353,441	-2,047,633	-33,836,855
Research and development expense	-721,953	-863,603	-29,256,678
Loss from operations	-2,607,294	-2,429,621	-57,909,086
Other income (expense):	'	'	'
Interest and exchange income (expense)	165	-2,178	56,212
Interest expense	-166,163	-158,255	-2,942,776
Debt conversion cost	0	0	-724,623
Gain on debt settlement	0	0	13,834
Loss on asset disposal	-24,768	-15,773	-63,955
Derivative income	65,922	0	445,908
Total other income (expense)	-124,844	-176,206	-3,215,400
Loss before income taxes	-2,732,138	-2,605,827	-61,124,486
Income taxes	0	0	0
Net loss	-2,732,138	-2,605,827	-61,124,486
Foreign currency translation adjustment	769	-11,520	23,934
Total comprehensive loss	($2,731,369)	($2,617,347)	($61,100,552)
Net loss per share - basic and diluted (in dollars per share)	($0.04)	($0.08)	($4.19)
Weighted average number of shares outstanding - basic and diluted (in shares)	65,455,791	34,517,601	14,569,103

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2013	($3,011,025)	$6,545	$55,351,613	($58,392,348)	$23,165
Balance (in shares) at Dec. 31, 2013	'	65,442,735	'	'	'
Issuance costs	-12,500	0	-12,500	0	0
Issuance of stock for services	12,500	2	12,498	0	0
Issuance of stock for services (in shares)	'	25,000	'	'	'
Stock-based compensation expense	117,989	0	117,989	0	0
Stock warrants issued for services	17,976	0	17,976	0	0
Stock warrants issued for services (in shares)	'	0	'	'	'
Net loss	-2,732,138	0	0	-2,732,138	0
Foreign currency translation adjustment	769	0	0	0	769
Balance at Mar. 31, 2014	($5,606,429)	$6,547	$55,487,576	($61,124,486)	$23,934
Balance (in shares) at Mar. 31, 2014	'	65,467,735	'	'	'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical) (USD $)	3 Months Ended
	Mar. 31, 2014
Net of Stock Issuance Cost	$12,500
Equity Par Value Of Company	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		153 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities:	'	'	'
Net loss	($2,732,138)	($2,605,827)	($61,124,486)
Adjustments to reconcile net loss to net cash from operating activities:	'	'	'
Depreciation and amortization	206,046	204,752	5,449,428
Non-cash compensation	117,989	76,657	2,517,133
Issuance of common stock and warrants for services	30,476	25,000	905,292
Issuance of common stock for accrued interest	0	0	833,432
Accretion of convertible debenture discount	65,706	5,608	396,386
Debt conversion costs associated with inducement	0	0	724,623
Loss on disposal of fixed assets	24,768	16,100	63,955
Bad debt expense	2,000	0	36,032
(Income) Expense from change in value of derivative	-65,922	0	-445,908
Net change in assets and liabilities:	'	'	'
Trade accounts receivable	99,518	-276,192	-151,378
Prepaid expenses	170,074	-20,475	-134,622
Other receivables	-1,575	-3,163	26,224
Inventory	-88,029	304,473	-553,363
Increase (decrease)	'	'	'
Trade accounts payable	657,438	-1,029,659	1,058,150
Other payables and accrued expenses	-206,665	440,526	862,501
Option fee	300,000	0	300,000
Net cash used in operating activities	-1,420,314	-2,862,200	-49,236,601
Cash flows from investing activities:	'	'	'
Purchase of and deposits on equipment	-51,935	-9,500	-5,022,308
Proceeds from sale of equipment	0	0	48,450
Net cash used in investing activities	-51,935	-9,500	-4,973,858
Cash flows from financing activities:	'	'	'
Net advances on bank line of credit	275,000	0	3,000,000
Proceeds from sale of common stock, net	-12,500	2,144,526	35,108,347
Proceeds from short and long-term debt	0	0	13,624,500
Proceeds from shareholder debt	605,000	225,000	5,003,216
Repayment of long-term debt	-21,204	-24,832	-2,322,700
Proceeds from Obligation related to the Letter of Credit	0	600,000	600,000
Repayment of Obligation related to the Letter of Credit	-147,860	0	-509,165
Financing costs	0	0	-4,387
Net cash provided by financing activities	698,436	2,944,694	54,499,811
Effect of exchange rate changes on cash	769	-11,520	23,934
Net increase (decrease) in cash	-773,044	61,474	313,286
Cash, beginning of period	1,086,330	27,604	0
Cash, end of period	313,286	89,078	313,286
Supplemental disclosure of cash flow information:	'	'	'
Cash paid during the period for interest	64,630	45,714	1,691,031
Supplemental disclosure of non-cash investing and financing activities:	'	'	'
Financed equipment	617,457	0	3,886,181
Debt converted to company stock	$0	$0	$15,273,658

Description_of_Company_and_Nat

Description of Company and Nature of Business	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
		1	Description of Company and Nature of Business
	Protea Biosciences Group, Inc. (referred to as “Protea”, “the Company”, “we”, “us” and “our”) is a commercial stage, molecular information company incorporated in the state of Delaware on May 24, 2005. “Molecular information” is the identification and characterization of the proteins, metabolites and other biomolecules, which are the products of all living cells and life forms. The Company is applying its technology to the development of next generation, “direct molecular imaging” technology and service capabilities that it believes enable more rapid and comprehensive molecular profiling of living cells and biofluids, thereby providing better molecular information that helps to define normal and disease processes. We believe that our proprietary technology is useful to support medical research and pharmaceutical development. The Company’s technologies enable the direct molecular imaging of the proteins, metabolites and other biomolecules that regulate the biological functions of the human body and all other forms of life. Management believes this is a critical area of research, as pharmaceutical research is in need of direct molecular imaging to improve and accelerate the development of new therapeutics and diagnostic tests.
	The consolidated balance sheet presented as of December 31, 2013, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes included in this report should be read in conjunction with the financial statements and notes included in the Company’s 2013 year-end audit.
	The accompanying financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The loss from operations since inception had an accumulated deficit at March 31, 2014 of approximately $58 million and at December 31, 2013 of approximately $55 million. The Company has funded its activities to date almost exclusively from debt and equity financings. The Company will continue to require substantial funds to advance the research and development of its core technologies and to develop new products and services based upon its proprietary protein recovery and identification technologies.
	Management intends to meet its operating cash flow requirements primarily from the sale of equity and debt securities. The Company seeks additional capital through sales of equity securities or convertible debt and, if appropriate, to pursue partnerships to advance various research and development activities. The Company may also consider the sale of certain assets, or entering into a transaction such as a merger with a business complimentary to theirs.
	While the Company believes that it will be successful in obtaining the necessary financing to fund its operations, they have no committed sources of funding and are not assured that additional funding will be available to them. These factors raise substantial doubt about the Company’s ability to continue as a going-concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2	Summary of Significant Accounting Policies
	The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s 10-K for the year ended December 31, 2013.
	Revenue Recognition
	We follow the provisions of FASB ASC 605, “Revenue Recognition”. We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses.
	We account for shipping and handling costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized.
	Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered.
	For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement.
	Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants.
	The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Revenue by component was as follows:
			Three Months Ended
			March 31, 2014			March 31, 2013
	Molecular Information Services		$	170,570		$	70,730
	LAESI Instrument Platform			178,000			296,694
	Research Products			95,342			114,191
	Grants and Other Collaborations			24,188			-
	Gross Revenue		$	468,100		$	481,615
	Other Receivables
	Other receivables, which reflect amounts due from non-trade activity, consist of the following at:
			March 31, 2014			December 31, 2013
	French government R&D credit		$	399,971		$	400,379
	French payroll taxes receivable			36,900			34,899
	Other receivables – current		$	436,871		$	435,278
	Deposits		$	23,231		$	23,249
	Other receivables – noncurrent		$	23,231		$	23,249
	Other Payables and Accrued Expenses
	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
			March 31, 2014			December 31, 2013
	Accrued expenses		$	411,688		$	653,047
	Accrued interest			75,738			39,911
	Accrued warranties			97,500			81,250
	Accrued payroll and benefits			275,374			286,979
	Unearned revenue			2,200			7,980
	Other payables and accrued expenses		$	862,500		$	1,069,167
	Derivative Liabilities
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
	Fair value of financial assets and liabilities – Derivative Instruments
	We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The three levels of inputs used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities.
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.
	Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants).
	The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities, at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations.
	The Company’s derivative liabilities are related to common stock issuances, detachable common stock purchase warrants (“warrants”) issued in conjunction with debt and common stock, or warrants issued to placement agents for financial instrument issuances. We estimate fair values of the warrants that contain anti-dilution or “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial”, “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes”, such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs.  Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation”, for which we engaged an independent valuation firm to perform) is the probability of a future capital raise.  By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts.
	As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable.  For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique.  This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input.   A range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows:
			March 31, 2014
			Expected Life		Risk Free				Probability of a Capital
			(Years)		Rate		Volatility		Raise
	Derivative liabilities		<1 – 4.75		0.93	%	80.23	%	100	%
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. The derivative liabilities measured at fair value on a recurring basis are summarized below:
			Fair Value Measurements at March 31, 2014
			Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock		$	464,506		-		-		$	464,506
	Derivative liabilities – warrants			93,159		-		-			93,159
	Total		$	557,665		-		-		$	557,665
			Fair Value Measurements at December 31, 2013
			Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock		$	558,799		-		-		$	558,799
	Derivative liabilities – warrants			64,788		-		-			64,788
	Total		$	623,587		-		-		$	623,587
	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
			Three Months Ended March 31, 2014
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
Balance at January 1, 2014		$	558,799		$	64,788		$	623,587
Issuance of warrants			-			-			-
Unrealized (gain) loss on derivative liabilities			-94,293			28,371			-65,922
Recognition of derivative liabilities			-			-			-
Balance at March 31, 2014		$	464,506		$	93,159		$	557,665
		Year Ended December 31, 2013
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
Beginning balance at January 1, 2013		$	-		$	-		$	-
Issuance of warrants			-			45,685			45,685
Unrealized (gain) loss on derivative liabilities			-257,846			-122,140			-379,986
Recognition of derivative liabilities			816,645			141,243			957,888
Balance at December 31, 2013		$	558,799		$	64,788		$	623,587
Net Loss per Share
Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 60,826,000 and 56,711,000 at March 31, 2014 and December 31, 2013, respectively.
RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS:
None

Inventory

Inventory	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	3	Inventory
	Inventory represents finished goods and work in progress. Finished goods and work in progress consist primarily of specifically identifiable items that are valued at the lower of cost or fair market value using the first-in, first-out (FIFO) method. Inventory consists of the following at:
	Inventory:		March 31, 2014		December 31, 2013
	Finished goods		$	217,667	$	360,607
	Work in progress			335,696		104,727
	Total Inventory		$	553,363	$	465,334

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	4	Property and Equipment
	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows:
	Equipment	5 - 10 years
	Vehicle	5 years
	Leasehold improvements	3 years
	Software	3 years
	Property and equipment consists of the following at:
			March 31, 2014		December 31, 2013
	Lab equipment		$	7,222,196	$	6,620,662
	Computer equipment			600,318		563,976
	Office equipment and vehicle			248,490		248,490
	Leasehold improvements			477,682		477,682
				8,548,686		7,910,810
	Accumulated depreciation			-5,223,933		-5,024,634
	Property and equipment, net		$	3,324,753	$	2,886,176
	For the three months ended March 31, 2014, depreciation expense was $206,046 compared to $204,752 for the three months ended March 31, 2013.

Bank_Line_of_Credit

Bank Line of Credit	3 Months Ended
	Mar. 31, 2014
Bank Line of Credit [Abstract]	'
Bank Line of Credit [Text Block]	'
	5	Bank Line of Credit
	The Company has a line of credit that is authorized to $3,000,000 and payable on demand. The interest rate is variable and is .75% plus prime with a minimum rate of 5.87%. The line of credit is subject to an annual review and certain covenants. At March 31, 2014, the balance was $3,000,000 compared to $2,725,000 at December 31, 2013 with interest payable at 5.87% and all covenants had been met. Borrowings under the line are secured by the personal guarantee of three board members and the estate of a former board member.

Loans_Payable_to_Stockholders

Loans Payable to Stockholders	3 Months Ended
	Mar. 31, 2014
Loan Payable [Abstract]	'
Loans Payable to Stockholders [Text Block]	'
	6	Loans Payable to Stockholders
	On August 6, 2013, the Company entered into the Note and Warrant Purchase Agreement (the “Summit Agreement”) with Summit, an affiliate of Steve Antoline, a director of the Company, pursuant to which Summit acquired (a) a promissory note (the “Summit Note”) bearing simple interest at a rate of 10% per annum, in an aggregate principal amount of $600,000 and (b) a five year warrant to purchase 1,000,000 shares of common stock at an exercise price of $1.10 per share. The fair value of these warrants was estimated to be $134,117, which was recorded as a discount to the promissory note, and will be accreted based on the repayment of the obligation. No accretion expense was recognized during the three months ended March 31, 2014 or in 2013. In accordance with the terms of the Summit Agreement, up to $150,000 of the gross proceeds received by the Company from the sale of each LAESI instrument shall be used to repay the principal amounts due under the Summit Note.
	On March 5, 2014, the Company received advances equal to an aggregate of $30,000 from Stanley Hostler, a director of the Company. No terms of repayment have been specified on the aforementioned advances as of the filing date.
	On March 17, 2014, the Company received an advance equal to $175,000 from El Coronado Holdings, Inc. (“El Coronado”). Josiah Austin is the managing member of El Coronado and a director of the Company. On April 2, 2014, in exchange for the advance, the Company entered into a Note Purchase Agreement, and issued a convertible one-year promissory note to El Coronado, in the aggregate principal amount of $175,000 to accrue simple interest at the rate of 10% per annum. Each $100,000 of outstanding principal and accrued unpaid interest underlying the note is automatically convertible into units consisting of 181,818 shares of common stock and warrants to purchase 109,091 shares of common stock at an exercise price of $0.80 per share or such alternate conversion rate as shall be consistent with the terms of a subsequent financing of the Company of at least $2 million in gross proceeds. (See Note 18, Subsequent Events.)
	On March 26, 2014 and April 10, 2014, the Company received an advance equal to $400,000 and $200,000 respectively from Summit Resources, Inc. (“Summit”). On April 2 and April 11, 2014, in exchange for advances, the Company entered into a Note and Warrant Purchase Agreement and issued (a) one-year promissory notes to Summit in an aggregate principal amount of up to $600,000 to accrue simple interest at the rate of 10% per annum and (b) five-year warrants to purchase up to 600,000 shares of common stock at an exercise price of $0.80 per share. (See Note 18, Subsequent Events.)

Obligation_Related_to_the_Lett

Obligation Related to the Letter of Credit	3 Months Ended
	Mar. 31, 2014
Obligation Related to Letter of Credit [Abstract]	'
Obligation Related to Letter of Credit [Text Block]	'
	7	Obligation Related to the Letter of Credit
	On March 6, 2013, the Company entered into a Warrant Purchase and Reimbursement Agreement, (the “Reimbursement Agreement”) with Steve Antoline, a director of the Company, pursuant to which Mr. Antoline agreed to issue a letter of credit, dated February 25, 2013 (the "Letter of Credit") for the benefit of MPR Associates, Inc. ("MPR") for the purpose of guaranteeing an amount equal to $600,000 (the “Purchase Order Amount”) due by the Company to MPR in connection with the production of certain LAESI instruments in exchange for (a) the agreement by the Company to reimburse Mr. Antoline for any amounts paid by him on behalf of the Company pursuant to the Letter of Credit, up to the Purchase Order Amount and (b) a five-year warrant to purchase up to 1,100,000 shares of common stock, issued to an affiliate of Mr. Antoline. The fair value of these warrants was estimated to be $138,763, which was recorded as a discount to the Reimbursement Agreement balance of $600,000, and has been accreted based on the repayment of the obligation. Accretion expense of $34,196 was recognized during the three months ended March 31, 2014 while $83,559 was recognized in 2013. During the first quarter of 2013, MPR drew $600,000 against the Letter of Credit.
	On June 14, 2013, the Company received $147,860 as payment for one of the LAESI instruments. The Company and Mr. Antoline entered into an Addendum to the Reimbursement Agreement whereby the Company could use the funds for up to 80 days or until September 1, 2013. The Addendum was further amended to extend the maturity date until December 31, 2013. For the period the funds were used by the Company, the balance accrued simple interest of 10% per annum. In addition, the Company will also issue a five-year warrant to purchase 250,000 shares of common stock at an exercise price of $1.10 per share upon the repayment of the funds. The fair value of these warrants was estimated to be $31,510, which was recorded as a discount to the Addendum balance of $147,860. During the three months ended March 31, 2014, the Addendum was paid in full and $31,510 of accretion expense was recognized. No accretion expense was recognized in 2013. As of March 31, 2014, $90,835 was due in connection with the terms of the Reimbursement Agreement compared to $238,695 as of December 31, 2013. Subsequent to March 31, 2014, the Reimbursement Agreement was paid in full.

Longterm_Debt

Long-term Debt	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Long-term Debt [Text Block]	'
	8	Long-term Debt
		1)	Note Payable to the West Virginia Development Office (“WVDO”)
	In March 2007, the Company obtained an 8-year loan in the amount of $685,000 from the WVDO. The note bears interest at 3% providing for 96 monthly principal and interest payments of $8,035 through April 2015, at which time the note is due and payable. The note is secured by equipment costing $1,057,167. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVDO approved a deferral of principal and interest until June 30, 2014.
		2)	Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In August 2009, the Company obtained a 10-year loan in the amount of $242,631 from the WVEDA. The note bears interest at 4% providing for 120 monthly principal and interest payments of $2,457 through August 2019, at which time the note is due and payable. The note is secured by 50% of equipment costing $569,812. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVEDA approved a deferral of principal and interest until May 31, 2014.
		3)	Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”)
	In August 2009, the Company obtained a 10-year loan in the amount of $242,630 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $2,371 through August 2019, at which time the note is due and payable. The note is secured by 50% of equipment costing $569,812. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until June 30, 2014.
		4)	Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In October 2010, the Company issued a 10-year note in the amount of $900,000 from the WVEDA. The note bears interest at 3.26% providing for 120 monthly principal and interest payments of $8,802 through October 2020, at which time the note is due and payable. The note is secured by equipment costing $997,248. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVEDA approved a deferral of principal and interest until May 31, 2014.
		5)	Note Payable to the West Virginia Infrastructure and Jobs Development Council (“WVIJDC”)
	In December 2010, the Company issued a 10-year note in the amount of $900,000 from the WVIJDC. The note bears interest at 3.25% providing for 120 monthly principal and interest payments of $8,781 through December 2020, at which time the note is due and payable. The note is secured by equipment costing $1,098,249. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the WVIJDC approved a deferral of principal and interest until June 30, 2014.
		6)	Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”)
	In March 2012, the Company issued an 18-month note in the amount of $290,000 from the WVJITB. The note bears interest at 6% providing for monthly interest-only payments starting April 2012 through August 2013, then final interest and principal payments due September 2013. The note has an adjustable conversion price, initially $2.00 per share, and includes a stock warrant for 72,500 shares (see Note 9, Stock Warrants). On December 13, 2013, the Company and the WVJITB entered into a Loan Modification Agreement whereby the maturity date changed from September 14, 2013 to $100,000 due on March 15, 2014 and the remaining $190,000 due on June 15, 2014. The WVJITB and the Company signed two addendums to the note extending the maturity date and deferring interest and principal payments until June 15, 2014. C. Andrew Zulauf, an executive member of the WVJITB, is a board member of the Company.
		7)	Convertible Promissory Note Payable to the West Virginia Jobs Investment Trust Board (“WVJITB”)
	In April 2012, the Company issued a 3-month note in the amount of $400,000 from the WVJITB. The note bears interest at 10% providing for monthly interest-only payments starting May 2012 through June 2012, then final interest and principal payments due July 2012. The note includes a stock warrant for 88,889 shares (see Note 9, Stock Warrants). The WVJITB and the Company have signed several addendums to the note extending the maturity date and reducing the price of converting into common shares to $0.50 per share. The WVJITB further extended the maturity date until November 29, 2013, with a $100,000 principal payment due on or before November 15, 2013. The Company repaid the $100,000 as agreed, which reduced the principal outstanding balance to $300,000. The WVJITB and the Company signed three addendums to the note extending the maturity date and deferring interest and principal payments until June 15, 2014. C. Andrew Zulauf, an executive member of the WVJITB, is a board member of the Company.
		8)	Convertible Promissory Note Payable to the West Virginia High Technology Consortium Foundation (“WVHTCF”)
	In May 2012, the Company issued a 30-month note in the amount of $200,000 from the WVHTCF. The note bears interest at 8% providing for 25 monthly principal and interest payments of $9,001 starting December 2012 through November 2014, then final interest and principal payments due December 2014. The note is secured by 50% of equipment costing $447,320. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the West Virginia High Technology Consortium Foundation approved a deferral of principal and interest until May 31, 2014.
		9)	Note Payable to the West Virginia Economic Development Authority (“WVEDA”)
	In June 2012, the Company issued a 10-year note in the amount of $200,000 from the WVEDA. The note bears interest at 2% providing for 120 monthly principal and interest payments of $1,840 through June 2022, at which time the note is due and payable. The note is secured by 50% of equipment costing $447,320. As of March 31, 2014, the Company was in arrears on the note. The repayment terms were modified, whereby the West Virginia Economic Development Authority approved a deferral of principal and interest until May 31, 2014.
		10)	Capital Leases
	From time to time, in the normal course of business, the Company enters into capital leases to finance equipment. As of March 31, 2014, the Company had four capital lease obligations outstanding with imputed interest rates ranging from 2.9% to 8.0%. The leases require 36 monthly payments and begin to expire in April 2014 through May 2017. These leases are secured by equipment with an aggregate cost of $930,120. As of March 31, 2014, the Company was in arrears on three capital leases. Subsequent to March 31, 2014, one capital lease was paid in full. This lease was secured by equipment costing $95,527.
	Total debts outstanding are as follows:
					March 31, 2014		December 31, 2013
	1)		Note Payable to the WVDO		$	123,744	$	123,744
	2)		Note Payable to the WVEDA			147,306		147,306
	3)		Note Payable to the WVIJDC			145,078		145,078
	4)		Note Payable to the WVEDA			639,085		639,085
	5)		Note Payable to the WVIJDC			651,913		651,913
	6)		Note Payable to the WVJITB			290,000		290,000
	7)		Note Payable to the WVJITB			300,000		300,000
	8)		Note Payable to the WVHTCF			95,178		95,178
	9)		Note Payable to the WVEDA			170,932		170,932
	10)		Capital leases			412,278		71,077
			Total			2,975,514		2,634,313
			Less: current portion			-1,221,218		-1,054,053
			Long-term portion		$	1,754,296	$	1,580,260
	Future required minimum principal repayments over the next five years are as follows:
	Year Ending December 31:		Future Required Minimum Principal Repayments
	2014		$	1,104,334
	2015			390,360
	2016			360,217
	2017			345,839
	2018 & Thereafter			774,764
	Total		$	2,975,514

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Common Stock [Text Block]	'
	9	Common Stock
	The Company is authorized to issue a total of 210,000,000 shares of stock, of which 200,000,000 shares are designated common stock and 10,000,000 shares designated preferred stock.
	Common Stock – par value of $.0001 per share with one vote in respect of each share held. Holders of common stock do not have cumulative voting rights. The members of the Board of Directors are elected by the affirmative vote of the holders of a majority of the Company’s outstanding common stock.  Common stock issued are as follows:
						Price				Value of				Additional
			# Shares	Par		Per		Gross		Services		Par		Paid in
			Issued	Value		Share		Proceeds		Obtained		Value		Capital (1)
	Balance at December 31, 2013		65,442,735	$	0.0001		Various	$	53,694,771	$	829,132	$	6,545	$	54,517,358
	Issuance of stock (2)		25,000		0.0001	$	0.5		-		12,500		2		12,498
	Balance at March 31, 2014		65,467,735					$	53,694,771	$	841,632	$	6,547	$	54,529,856
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued for services performed and did not contain an anti-dilution provision

Preferred_Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	10	Preferred Stock
	The Company is authorized to issue preferred stock in one or more series and containing such rights, privileges and limitations, including voting rights, dividend rates, conversion privileges, redemption rights and terms, redemption prices and liquidation preferences, as the Board may, from time to time, determine. No shares of the Preferred Stock have been issued.

Stock_Options_and_Stockbased_C

Stock Options and Stock-based Compensation	3 Months Ended
	Mar. 31, 2014
Stock Options and Stock Based Compensation [Abstract]	'
Stock Options and Stock Based Compensation [Text Block]	'
	11	Stock Options and Stock-based Compensation
	In 2002, the Board adopted the 2002 Equity Incentive Plan (the “2002 Plan”) that governed equity awards to employees, directors and consultants of the Company. Under the Plan, 450,000 shares of common stock were reserved for issuance. From 2006 through 2012, the 2002 Plan was amended several times to increase the total number of shares authorized under the 2002 Plan to 4,150,000 shares. During the first quarter 2013, the Board adopted the 2013 Equity Incentive Plan (the “2013 Plan”) and together with the 2002 Plan (the “Plans”) governs the equity awards to employees, directors and consultants of the Company. Under the 2013 Plan, an additional 5,000,000 shares of common stock has been reserved for issuance. On June 18, 2013, the 2013 Plan was approved by holders of a majority of the issued and outstanding shares of common stock of the Company.
	The types of awards permitted under the Plans include qualified incentive stock options (ISO), non-qualified stock options (NQO), and restricted stock. Each option shall be exercisable at such times and subject to such terms and conditions as the Board may specify. Stock options generally vest over four years and expire no later than ten years from the date of grant.
	A summary of stock option activity is as follows:
								Weighted Average
					Weighted Average			Remaining
					Exercise			Contractual Life
			Shares		Price			(in years)
	Outstanding at December 31, 2013		5,082,750		$	1.11		7.02
	Granted		1,304,500		$	0.55
	Exercised		-			-
	Cancelled or expired		-87,500		$	1.5
	Outstanding at March 31, 2014		6,299,750		$	1.05		6.95
	Exercisable at December 31, 2013		4,005,583		$	1.2		6.52
	Exercisable at March 31, 2014		4,400,207		$	1.15		6.35
	The following table summarizes information about stock options at March 31, 2014:
	Options Outstanding									Options Exercisable
						Weighted Average		Weighted			Weighted
						Remaining Contractual		Average			Average
						Life (in years)		Exercise			Exercise
	Exercise Price			Outstanding				Price		Exercisable	Price
		$0.50		159,000						115,063
		$0.55		2,997,500						1,274,582
		$0.80		320,000						320,000
		$1.25		310,000						310,000
		$1.50		2,298,500						2,175,187
		$2.00		214,750						205,375
		$0.50 - $2.00		6,299,750		6.95		$	1.05	4,400,207	$	1.15
	At March 31, 2014 and December 31, 2013, the total aggregate intrinsic value for options currently exercisable and options outstanding was $0. These values represent the total pre-tax intrinsic value based on the estimated fair value of the Company’s stock price of $0.50 as of March 31, 2014 and December 31, 2013. In 2014 and 2013, no options were exercised.
	The following table summarizes the activity of the Company’s stock options that have not vested:
			Shares		Weighted Average Grant-date Fair Value
	Nonvested at December 31, 2013		1,077,167		$	0.467
	Granted		1,122,751		$	0.205
	Forfeited		-87,500		$	1.027
	Vested		-212,875		$	0.566
	Nonvested at March 31, 2014		1,899,543		$	0.203
	The fair value of non-vested options to be recognized in future periods is $296,831, which is expected to be recognized over a weighted average period of 2 years. The total fair value of options vested during the three months ended March 31, 2014 was $117,989 compared to $76,657 for the three months ended March 31, 2013.
	Stock-based compensation expense is as follows:
			Three Months Ended
			March 31, 2014			March 31, 2013
	Selling, general, and administrative expense		$	111,286		$	70,754
	Research and development expense			6,703			5,903
	Total stock-based compensation expense		$	117,989		$	76,657
	The weighted average grant-date fair value of options granted during the three months ended March 31, 2014 was $0.205 and for the three months ended March 31, 2013 was $0.112 per option. The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:
			Three Months Ended
			March 31, 2014		March 31, 2013
	Weighted average risk-free interest rate		2.35	%	0.14	%
	Volatility factor		73.56	%	24 - 73	%
	Weighted average expected life (in years)		7		7
	Dividend rate		0	%	0	%
	The Company utilizes a peer group to estimate its expected volatility assumptions used in the Black-Scholes option-pricing model. The Company completed an analysis and identified four similar companies considering their industry, stage of life cycle, size, and financial leverage. Given the Company’s limited history with stock options, the Company’s expected term is based on an average of the contractual term and the vesting period of the options (the SAB 110 “Simplified” method).

Stock_Warrants

Stock Warrants	3 Months Ended
	Mar. 31, 2014
Stock Warrants [Abstract]	'
Stock Warrants [Text Block]	'
	12	Stock Warrants
	From 2008 through 2014, the Company has issued warrants to purchase shares of common stock. The warrants are exercisable for five years from date of issuance and are exercisable at exercise prices that range from $0.50 to $2.25 per share.
	During 2013, the Company issued warrants mostly in connection with common stock issuances. The warrants are exercisable one or five years from date of issuance. The exercise price is $0.50 to $1.10 per share. The warrant allows the holder to purchase shares of common stock, and contains anti-dilution provisions that adjust the exercise price if certain equity instruments are issued (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. The anti-dilutive provisions have an expiration term of either one or five years from date of issuance. The anti-dilutive provision on 7,592,400 warrants expired on December 31, 2013.
	As of March 31, 2014, warrants to purchase 56,425,937 shares of common stock were outstanding and exercisable. The Company recognized a total of $65,706 in interest expense and $17,976 in consulting services during the three months ended March 31, 2014 and $537,137 in placement agent services as of December 31, 2013 as a result of issuing 3,720,323 warrants earned in 2014.
							Weighted Average
					Weighted Average		Remaining
					Exercise		Contractual Life
			Shares		Price		(in years)
	Outstanding at December 31, 2013		52,705,614		$	1.3	2.58
	Granted		3,720,323		$	0.77	4.84
	Exercised		-			-
	Cancelled or expired		-			-
	Outstanding at March 31, 2014		56,425,937		$	1.28	2.69
	The following table summarizes information about stock warrants at March 31, 2014:
	Warrants Outstanding
							Weighted
						Weighted Average	Average
						Remaining Contractual	Exercise
	Exercise Price			Outstanding		Life (in years)	Price
		$0.50		15,524,642
		$0.75		11,065,144
		$1.10		18,721,850
		$1.12		263,750
		$2.00		9,455,842
		$2.20		98,320
		$2.25		1,296,389
		$0.50 - $2.00		56,425,937		2.69	$	1.28

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	13	Income Taxes
	The provision for income taxes, if any, is comprised of current and deferred components. The current component, if any, presents the amount of federal and state income taxes that are currently reportable to the respective tax authorities and is measured by applying statutory rates to the Company’s taxable income as reported in its income tax returns. The Company has evaluated its income tax positions in accordance with FASB ASC 740. There were no changes to unrecognized tax benefits during 2013. The tax years 2009 through 2012 remain open to review by various taxing authorities.
	ASC Topic 740, Income Taxes defines the confidence level that a tax position must meet in order to be recognized in the financial statements. Accordingly, we have assessed uncertain tax positions in each of the tax jurisdictions in which we have operations and account for the related financial statement implications. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements on a particular tax position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. We recognize both accrued interest and penalties, where appropriate, related to unrecognized tax benefits in income tax expense.
	Significant management judgment is required in determining the provision for income taxes, deferred tax assets and liabilities, and any valuation allowance recorded in connection with the deferred tax assets.
	Deferred income taxes are provided for the temporary differences between the carrying values of the Company’s assets and liabilities for financial reporting purposes and their corresponding income tax basis. These temporary differences are primarily attributable to a net operating loss, which, due to income tax laws and regulations, become taxable or deductible in different years than their corresponding treatment for financial reporting purposes. The temporary differences give rise to either a deferred tax asset or liability in the financial statements, which is computed by applying statutory tax rates to taxable or deductible temporary differences based upon the classification (i.e., current or noncurrent) of the asset or liability in the financial statements which relate to the particular temporary difference. Deferred taxes related to differences that are not attributable to a specific asset or liability are classified in accordance with the future period in which they are expected to reverse and be recognized for income tax purposes.
	During the development stage of the Company when future benefit of the deferred tax asset is uncertain, the Company provides for a full valuation allowance against the deferred tax asset. Net operating loss carryforwards start to expire beginning 2021 for both federal and state purposes. The net operating tax loss carryforwards total approximately $51,500,000 and $50,000,000 at March 31, 2014 and December 31, 2013, respectively.

Lease_Commitments

Lease Commitments	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments Disclosure [Text Block]	'
	14	Lease Commitments
	The Company leases its USA facilities under operating leases beginning a) April 2012 through March 2017 and b) a month-to-month lease. Additionally, the Company leases its Europe facility on a three-year lease beginning January 2012 through January 2015. The Company also has three equipment operating leases with terms of three to five years.
	Future required minimum principal repayments over the next five years are as follows:
	Year ending December 31:		Future required minimum lease payments
	2014		$	183,943
	2015		$	167,628
	2016		$	167,628
	2017		$	41,907
	Rent expense totals $94,828 for the three month period ended March 31, 2014, compared to $109,498 for the three month period ended March 31, 2013.

Retirement_Plan

Retirement Plan	3 Months Ended
	Mar. 31, 2014
Retirement Plan [Abstract]	'
Retirement Plan [Text Block]	'
	15	Retirement Plan
	The Company provides a 401(k) Profit Sharing Plan (“401(k) Plan”) for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year. The Company, at its discretion, can make matching contributions to the 401(k) Plan. The Company may also make qualified non-elective contributions to participants who are not highly compensated employees. All employees meeting age and hours of service requirements are eligible to participate in the 401(k) Plan beginning their first full month of service. Participants become vested in employer contributions on a graduated scale with full vesting after five years. No company contributions have yet been made.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Matters and Contingencies [Text Block]	'
	16	Commitments and Contingencies
	Legal Proceedings
	The Company currently is not a party to any material legal proceeding and has no knowledge of any material legal proceeding contemplated by any governmental authority or third party. The Company may be subject to a number of claims and legal proceedings which, in the opinion of our management, are incidental to normal business operations. In managements’ opinion, although final settlement of these claims and suits may impact the financial statements in a particular period, they will not, in the aggregate, have a material adverse effect on the Company’s financial position, cash flows or results of operations.
	Indemnity of Directors and Officers
	As permitted under Delaware law and required by corporate by-laws, the Company indemnifies and holds harmless its directors and officers for certain events or occurrences while the director or officer is or was serving in such capacity. The maximum potential amount of future payments that could be required under these indemnification obligations is unlimited; however, the Company maintains a Directors and Officers liability insurance policy that enables it to recover a portion of any future amounts paid with a limit of liability of $5,000,000.  The Company may incur an additional liability if indemnity for more than the limit of liability occurred, and such liability may have a material adverse effect on its financial position, cash flows and results of operations. As there were no known or pending claims, the Company has not accrued a liability for such claims as of March 31, 2014.
	Warranty Costs
	The Company provides for a one year warranty with the sale of its LAESI instrument. All other product warranties are 90 days from the date of delivery of the goods. As the Company does not currently have sufficient historical data on warranty claims, the Company's estimates of anticipated rates of warranty claims and costs are primarily based on comparable industry metrics. The Company engages in extensive product quality programs and processes, including actively monitoring and evaluating the quality of its product. As of March 31, 2014, the Company recorded accrued warranty expense of $97,500 compared to $81,250 as of December 31, 2013.
	Stock Options
	The Company has an agreement with one board member for payment of services by stock options. The board member is to receive a stock option for 4,000 shares per month (awarded annually) with an exercise price equal to the current market price. The agreement is cancellable with 90 days’ notice.
	University License Agreements
	The Company has agreements with universities related to in-licensed technologies as follows:
	AGREEMENT WITH WEST VIRGINIA UNIVERSITY (WVU)
	The Company has entered into a License and Exclusive Option to License Agreement with the West Virginia University Research Corporation, a nonprofit West Virginia corporation (“WVURC”) acting for and on behalf of WVU. Under the terms of this Agreement, the WVURC has granted the Company an exclusive option to license technology from the laboratories of certain WVU principal investigators in the field of protein discovery, for therapeutic, diagnostic and all other commercial fields worldwide.
	Under the terms of this Agreement, the Company pays expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenue resulting from the sale of products and services that utilize the WVU subject technology.
	AGREEMENT WITH GEORGE WASHINGTON UNIVERSITY (GWU)
	In March 2009, the Company entered into an Exclusive License Agreement with George Washington University (Washington D.C.) for technology developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology and Applications, the Department of Chemistry, who is a science advisor to the Company. The technology field is LAESI - laser ablation electrospray ionization, a new method of bioanalytical analysis that enables high throughput biomolecule characterization.
	Under the terms of the license agreement, the Company has the exclusive, worldwide rights to commercialize the technology. The Company is obligated to pay expenses for the preparation, filing and prosecution of related patent applications, and the Company will pay royalties on the net revenues resulting from the sale of products and services that utilize the GWU subject technology. As of March 31, 2014, the Company accrued approximately $45,800 to GWU for royalties compared to $32,600 as of December 31, 2013.
	In November 2012, the Company entered into a Patent License Agreement with George Washington University (Washington D.C) for technology developed in the laboratory of Akos Vertes Ph.D. The technology field is Laser Desorption/Ionization and Peptide Sequencing on Laser-Induced Silicon Microcolumn Arrays (Matrix) and Nanophotonic Production, Modulation and Switching of Ions by Silicon Microcolumn Arrays.
	Under the terms of the license agreement, the Company has an exclusive, worldwide license to make, have made, use, import, offer for sale and sell the licensed products. The Company is obligated to pay a license initiation fee of $25,000 and a minimum license diligence resources of $12,500 in year two and $20,000 each year thereafter to develop and commercialize the products, $30,000 milestone payment upon the first sale of a licensed product, and royalties will be 7% of the net sales of licensed products and 5% of the net sales of combination products for combined cumulative net sales up to $50 million. Thereafter, royalties reduce to 6% and 4%, respectively, after taking into account quarterly minimum royalties of $1,500 for the first four quarters after the first sale of a licensed product, $2,500 for the next four quarters, $3,000 for the next four quarters and $6,000 for each succeeding quarter.
	In January 2014, the Company became a subcontractor to George Washington University in a multi-year project with the Defense Advanced Research Projects Agency (DARPA) to develop new tools and methods to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days of exposure.
	AGREEMENT WITH VIRGINIA TECH (VT)
	In 2010, the Company entered into an agreement with VT for the exclusive option to license technology in development in the laboratory of Rafael Davalos, PhD., which is intended to enable the separation of specific cell populations, such as cancer cells, in blood and other fluids. It also has an exclusive license to the IRAK-1 compound as a regulator of diseases and disorders in the lab of Liwu Li, PhD.
	ACREEMENT WITH OMICS2IMAGE
	In 2014, the Company entered into an agreement with Omics2Image related to the “Next Generation Ambient Imaging Mass Spectrometry for (Bio)polymers and Smart Materials” (“COAST Project”). The Company has committed to fund 60,000 Euros related to the COAST Project. Omics2Image agrees to evenly share the value gained from the efforts outlined within the scope of the COAST Project, which may include new intellectual property and the development of a commercial, integrated instrument system.
	Joint Pharmaceutical Development Agreement
	AGREEMENT WITH LABORATOIRE MAYOLY SPINDLER
	In May 2009, the Company, and its wholly-owned subsidiary, Proteabio Europe SAS, entered into a Joint Research and Development Agreement with Laboratories Mayoly Spindler SAS (Mayoly), a European Pharmaceutical company with headquarters in France, for the joint development of a recombinant lipase biopharmaceutical. Under terms of the agreement, Protea receives the exclusive marketing rights for the therapeutic in the territory of North America; will be responsible for paying 40% of the development expenses (with Mayoly funding the remaining 60%); will pay royalties on net sales of the biopharmaceutical, and a milestone payment of 1m Euros at the time the Company obtains the first FDA approval for the recombinant Lipase biotherapeutic. The Company also receives a sublicense to certain patents owned by Mayoly and licensed from the government of France. As of December 31, 2013 and December 31, 2012, the Company owed approximately $37,000 and $36,000 to Mayoly, which is reflected in Trade Accounts Payable on the Consolidated Balance Sheet.
	Engineering and Design Services
	The Company has engaged Dynamic Manufacturing LLC, a contract manufacturer to produce ten LAESI units. As of March 31, 2014, the Company had received three LAESI units from Dynamic. As of March 31, 2014, the Company had about $371,438 in outstanding commitments with Dynamic as well as approximately $198,000 in payables due to Dynamic.
	The Company has approximately $117,000 in outstanding commitments with Bridger Photonics for lasers related to the LAESI technology. At March 31, 2014, the Company owed approximately $8,000 in payables due to Bridger.

Option_Fee

Option Fee	3 Months Ended
	Mar. 31, 2014
Option Fee [Abstract]	'
Option Fee [Text Block]	'
	17	Option Fee
	Option Agreement with BioPharma d’Azur, Inc.
	On March 27, 2014, the Company entered into an Option Agreement by and among, the Company, ProteaBio Europe and BioPharma d’Azur, Inc. (“BioPharma”) pursuant to which BioPharma was granted a 90 day option (the “Option”) to acquire the business of Protea Europe (the “Acquisition”), including an assignment of the Amended and Restated Joint Research Agreement, by and among the Protea Sub, Protea Europe and Laboratoires Mayloy Spindler SAS, dated March 22, 2010, in exchange for a non-refundable fee equal to $300,000 (the “Option Fee”) payable by BioPharma to the Company. The exercise of the Option and the consummation of the acquisition will be conditioned upon BioPharma providing evidence that it has raised gross proceeds from an equity financing of at least an additional $300,000 (the “First Funding Amount”), exclusive of the Option Fee. If the option is not exercised, the Company will issue shares of common stock to BioPharma with an aggregate value of $300,000 determined by dividing the Option Fee by the greater of $0.55 or the 20 day volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. The terms of the Option Agreement provide that the First Funding Amount will be delivered to the Company upon the execution and signing of a definitive agreement with respect to the Acquisition. In addition, upon the consummation of the Acquisition, BioPharma will issue to the Company the number of shares of preferred stock of BioPharma (the “Preferred Shares”) that shall be convertible into no less than 33% of the issued and outstanding common stock of BioPharma following the Acquisition. The Preferred Shares will be subject to certain anti-dilution protection and vote together with the common stock of BioPharma on all matters.
	The Option Agreement will terminate upon the earlier of (i) BioPharma providing written notice of its election to terminate the Option Agreement; (ii) at the election of either party, if the other party has (A) breached any of its representations, warranties or covenants contained therein or (B) failed to perform any of its material obligations thereunder and has not cured such breach or failure within twenty (20) days after written notice by the other party thereof; (iii) the expiration of the option period; or (iv) the execution of a definitive agreement with respect to the Acquisition.

Evaluation_of_Subsequent_Event

Evaluation of Subsequent Events	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	18	Evaluation of Subsequent Events
	Common Stock
	Subsequent to the Balance Sheet date, the Company issued 87,348 shares of common stock to their attorneys for services rendered.
	Additionally, the Company issued 150,000 shares of common stock to a consultant for services rendered.
	Stock Warrants
	Subsequent to March 31, 2014, the Company issued warrants to purchase 600,000 shares of common stock to Summit Resources, Inc., an affiliate of Steve Antoline, a director of the Company, in connection with the April 2, 2014 and April 11, 2014 Promissory Notes. The warrants are exercisable at an exercise price of $0.80 per share for a five year term.
	Additionally, the Company issued warrants to purchase 187,500 shares of common stock to a consultant for services rendered. The warrants are exercisable at an exercise price of $1.10 per share for a five year term.
	Stock Options
	Subsequent to March 31, 2014, the Company granted options to purchase an aggregate of 1,042,500 shares of common stock to various employees in connection with the Company’s 2013 Equity Incentive Plan at an exercise price of $0.55 per share.
	Advances from Stockholders
	Subsequent to March 31, 2014, the Company received advances equal to an aggregate of $20,000 from certain current directors and related parties. No terms of repayment have been specified on the aforementioned advances as of the filing date.
	On April 2, 2014, the Board approved an offering of up to $900,000 consisting of (a) one year promissory notes in an aggregate principal amount equal to the amount to be borrowed and disbursed by certain related parties with interest to accrue at a rate of 10% per annum; and (b) five year warrants to purchase up to 900,000 shares of common stock at an exercise price of $0.80 per share. As of the date of this filing, the Company has issued notes in an aggregate principal amount of $650,000 and warrants to purchase up to 650,000 shares of common stock to related parties.
	Issuance of Convertible Debentures
	In addition, on April 2, 2014, the Board also approved an offering of up to $300,000 in convertible one year promissory notes. Each $100,000 of outstanding principal and accrued unpaid interest underlying the note is automatically convertible upon the final closing of a subsequent financing of at least $2 million in gross proceeds into units consisting of 181,818 shares of common stock and warrants to purchase up to 109,091 shares of common stock at an exercise price of $0.80 per share or such alternate conversion rate as shall be consistent with the terms of a subsequent financing. On April 22, 2014, the Board approved an increase in the total offering amount of convertible notes issuable to $1,100,000. As of the filing date, the Company has issued an aggregate of $426,000 in convertible notes.
	Repayment on the Obligation Related to the Letter of Credit
	Subsequent to March 31, 2014, the Company made a payment of approximately $90,835 to Steve Antoline. The payment satisfied the Obligation Related to the Letter of Credit.
	Repayment on Loans Payable to Stockholders
	Subsequent to March 31, 2014, the Company made a payment of approximately $59,165 to Steve Antoline on the August 6, 2013 promissory note. The payment reduced the outstanding balance to $540,835.
	Promissory Note
	Subsequent to March 31, 2014, the Company issued a 3-month promissory note of $100,000 to BioPharma d’Azur, Inc. The note bears interest at 6% per annum.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Revenue Recognition, Deferred Revenue [Policy Text Block]	'
	Revenue Recognition
	We follow the provisions of FASB ASC 605, “Revenue Recognition”. We recognize revenue of products when persuasive evidence of a sale arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred /title has passed, and collectability of the sales price is reasonably assured. The Company recognizes revenue from the sale of its ProteaPlot™ software when bundled with the LAESI platform, which facilitates operating the instrument and storage and display of datasets. The Company also recognizes revenue of standalone sales of ProteaPlot™, which generally consists of additional user licenses.
	We account for shipping and handling costs in accordance with the provisions of FASB ASC 605-45-45, “Revenue Recognition – Principal Agent Considerations”, which requires all amounts charged to customers for shipping and handling to be classified as revenues. Shipping and handling costs charged to customers are recorded in the period the related product sales revenue is recognized.
	Regarding short-term service contracts, the majority of these service contracts involve the processing of imaging and bioanalytical samples for pharmaceutical and academic/clinical research laboratories. These contracts generally provide for a fixed fee for each method developed or sample processed and revenue is recognized when the analysis is complete and a report is delivered.
	For longer-term contracts involving multiple elements, the items included in the arrangement (deliverables) are evaluated to determine whether they represent separate units of accounting. We perform this evaluation at the inception of an arrangement and as each item in the arrangement is delivered. Generally, we account for a deliverable (or a group of deliverables) separately if: (i) the delivered item(s) have standalone value to the customer, and the delivery or performance of the service(s) is probable and substantially in our control. Revenue on multiple revenue arrangements is recognized using a proportional method for each separately identified element. All revenue from contracts determined not to have separate units of accounting is recognized based on consideration of the most substantive delivery factor of all the elements in the contract or, if there is no predominant deliverable, upon delivery of the final element of the arrangement.
	Revenues from grants are based upon internal costs that are specifically covered by the grants, and where applicable, an additional facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by the Company that is related to the grants.
	The Company has revenue from four major components: molecular information services, LAESI instrument platform, research products, and grants and other collaboration revenues. Revenue by component was as follows:
		Three Months Ended
		March 31, 2014			March 31, 2013
	Molecular Information Services	$	170,570		$	70,730
	LAESI Instrument Platform		178,000			296,694
	Research Products		95,342			114,191
	Grants and Other Collaborations		24,188			-
	Gross Revenue	$	468,100		$	481,615
Receivables, Policy [Policy Text Block]	'
	Other Receivables
	Other receivables, which reflect amounts due from non-trade activity, consist of the following at:
		March 31, 2014			December 31, 2013
	French government R&D credit	$	399,971		$	400,379
	French payroll taxes receivable		36,900			34,899
	Other receivables – current	$	436,871		$	435,278
	Deposits	$	23,231		$	23,249
	Other receivables – noncurrent	$	23,231		$	23,249
Other Payables and Accrued Expenses [Policy Text Block]	'
	Other Payables and Accrued Expenses
	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
		March 31, 2014			December 31, 2013
	Accrued expenses	$	411,688		$	653,047
	Accrued interest		75,738			39,911
	Accrued warranties		97,500			81,250
	Accrued payroll and benefits		275,374			286,979
	Unearned revenue		2,200			7,980
	Other payables and accrued expenses	$	862,500		$	1,069,167
Derivatives, Embedded Derivatives [Policy Text Block]	'
	Derivative Liabilities
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks; however, the Company has certain financial instruments that are embedded derivatives associated with capital raises and common stock purchase warrants. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with FASB ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion or exercise, the derivative liability is marked to fair value at the conversion date and then the related fair value is reclassified to equity.
Fair Value Measurement, Policy [Policy Text Block]	'
	Fair value of financial assets and liabilities – Derivative Instruments
	We measure the fair value of financial assets and liabilities in accordance with GAAP, which defines fair value, establishes a framework for measuring fair value, and requires certain disclosures about fair value measurements.
	GAAP defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. GAAP also establishes the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
	The three levels of inputs used to measure fair value:
	Level 1 – quoted prices in active markets for identical assets or liabilities.
	Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable.
	Level 3 – inputs that are unobservable (for example, the probability of a capital raise in a “binomial” methodology for valuation of a derivative liability directly related to the issuance of common stock warrants).
	The Company has entered into certain financial instruments and contracts such as, equity financing arrangements for the issuance of common stock, which include anti-dilution arrangements and detachable stock warrants that are i) not afforded equity classification, ii) embody risks not clearly and closely related to host contracts, or iii) may be net-cash settled by the counterparty. These instruments are recorded as derivative liabilities, at fair value at the issuance date. Subsequent changes in fair value are recorded through the statement of operations.
	The Company’s derivative liabilities are related to common stock issuances, detachable common stock purchase warrants (“warrants”) issued in conjunction with debt and common stock, or warrants issued to placement agents for financial instrument issuances. We estimate fair values of the warrants that contain anti-dilution or “Down Round Protections” utilizing valuation models and techniques that have been developed and are widely accepted that take into account the additional value inherent in “Down Round Protection.” These widely accepted techniques include “Modified Binomial”, “Monte Carlo Simulation” and the “Lattice Model.” The “core” assumptions and inputs to the “Binomial” model are the same as for “Black-Scholes”, such as trading volatility, remaining term to maturity, market price, strike price, and risk free rates; all Level 2 inputs.  Fair value measurements are classified according to the lowest level input or value-driver that is significant to the valuation. A measurement may therefore be classified within Level 3 even though there may be significant inputs that are readily observable. However, a key input to a “Binomial” model (in our case, the “Monte Carlo Simulation”, for which we engaged an independent valuation firm to perform) is the probability of a future capital raise.  By definition, this input assumption does not meet the requirements for Level 1 or Level 2 outlined above; therefore, the entire fair value calculation is deemed to be Level 3 under accounting requirements due to this single Level 3 assumption. This input to the Monte Carlo Simulation model was developed with significant input from management based on its knowledge of the business, current financial position and the strategic business plan with its best efforts.
	As discussed above, financial liabilities are considered Level 3 when their fair values are determined using pricing models or similar techniques and at least one significant model assumption or input is unobservable.  For the Company, the Level 3 financial liability is the derivative liability related to the common stock and warrants that include “Down Round Protection” and they were valued using the “Monte Carlo Simulation” technique.  This technique, while the majority of inputs are Level 2, necessarily incorporates a Capital Raise Assumption which is unobservable and, therefore, a Level 3 input.   A range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows:
		March 31, 2014
		Expected Life		Risk Free				Probability of a Capital
		(Years)		Rate		Volatility		Raise
	Derivative liabilities	<1 – 4.75		0.93	%	80.23	%	100	%
	Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
	The Company’s derivative liabilities are related to common stock issuances, detachable warrants issued in conjunction with debt and common stock, or warrants issued to the placement agents for financial instrument issuances. The derivative liabilities measured at fair value on a recurring basis are summarized below:
		Fair Value Measurements at March 31, 2014
		Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock	$	464,506		-		-		$	464,506
	Derivative liabilities – warrants		93,159		-		-			93,159
	Total	$	557,665		-		-		$	557,665
		Fair Value Measurements at December 31, 2013
		Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock	$	558,799		-		-		$	558,799
	Derivative liabilities – warrants		64,788		-		-			64,788
	Total	$	623,587		-		-		$	623,587
	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
		Three Months Ended March 31, 2014
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
	Balance at January 1, 2014	$	558,799		$	64,788		$	623,587
	Issuance of warrants		-			-			-
	Unrealized (gain) loss on derivative liabilities		-94,293			28,371			-65,922
	Recognition of derivative liabilities		-			-			-
	Balance at March 31, 2014	$	464,506		$	93,159		$	557,665
		Year Ended December 31, 2013
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
	Beginning balance at January 1, 2013	$	-		$	-		$	-
	Issuance of warrants		-			45,685			45,685
	Unrealized (gain) loss on derivative liabilities		-257,846			-122,140			-379,986
	Recognition of derivative liabilities		816,645			141,243			957,888
	Balance at December 31, 2013	$	558,799		$	64,788		$	623,587
Earnings Per Share, Policy [Policy Text Block]	'
	Net Loss per Share
	Basic and diluted loss per common share is computed based on the weighted average number of common shares outstanding. Common share equivalents (which may consist of options, warrants and convertible debt) are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, totaled approximately 60,826,000 and 56,711,000 at March 31, 2014 and December 31, 2013, respectively.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS:
	None

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Revenue by component was as follows:
		Three Months Ended
		March 31, 2014			March 31, 2013
	Molecular Information Services	$	170,570		$	70,730
	LAESI Instrument Platform		178,000			296,694
	Research Products		95,342			114,191
	Grants and Other Collaborations		24,188			-
	Gross Revenue	$	468,100		$	481,615
Summary of Trade and Other Receivables [Table Text Block]	'
	Other receivables, which reflect amounts due from non-trade activity, consist of the following at:
		March 31, 2014			December 31, 2013
	French government R&D credit	$	399,971		$	400,379
	French payroll taxes receivable		36,900			34,899
	Other receivables – current	$	436,871		$	435,278
	Deposits	$	23,231		$	23,249
	Other receivables – noncurrent	$	23,231		$	23,249
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Other payables and accrued expenses, which reflect amounts due from non-trade activity, consist of the following at:
		March 31, 2014			December 31, 2013
	Accrued expenses	$	411,688		$	653,047
	Accrued interest		75,738			39,911
	Accrued warranties		97,500			81,250
	Accrued payroll and benefits		275,374			286,979
	Unearned revenue		2,200			7,980
	Other payables and accrued expenses	$	862,500		$	1,069,167
Fair Value Inputs, Instruments Classified in Shareholders Equity, Quantitative Information [Table Text Block]	'
	A range of key quantitative assumptions related to the common stock and warrants that include “Down Round Protection” are as follows:
		March 31, 2014
		Expected Life		Risk Free				Probability of a Capital
		(Years)		Rate		Volatility		Raise
	Derivative liabilities	<1 – 4.75		0.93	%	80.23	%	100	%
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The derivative liabilities measured at fair value on a recurring basis are summarized below:
		Fair Value Measurements at March 31, 2014
		Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock	$	464,506		-		-		$	464,506
	Derivative liabilities – warrants		93,159		-		-			93,159
	Total	$	557,665		-		-		$	557,665
		Fair Value Measurements at December 31, 2013
		Carrying Value			Level 1		Level 2		Level 3
	Derivative liabilities – common stock	$	558,799		-		-		$	558,799
	Derivative liabilities – warrants		64,788		-		-			64,788
	Total	$	623,587		-		-		$	623,587
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	'
	The table below provides a summary of the changes in fair value of the derivative liabilities measured at fair value on a recurring basis:
		Three Months Ended March 31, 2014
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
	Balance at January 1, 2014	$	558,799		$	64,788		$	623,587
	Issuance of warrants		-			-			-
	Unrealized (gain) loss on derivative liabilities		-94,293			28,371			-65,922
	Recognition of derivative liabilities		-			-			-
	Balance at March 31, 2014	$	464,506		$	93,159		$	557,665
		Year Ended December 31, 2013
								Total Fair Value
		Derivative			Derivative			Measurements
		Liabilities -			Liabilities -			Using Level 3
		Common Stock			Warrants			Inputs
	Beginning balance at January 1, 2013	$	-		$	-		$	-
	Issuance of warrants		-			45,685			45,685
	Unrealized (gain) loss on derivative liabilities		-257,846			-122,140			-379,986
	Recognition of derivative liabilities		816,645			141,243			957,888
	Balance at December 31, 2013	$	558,799		$	64,788		$	623,587

Inventory_Tables

Inventory (Tables)	3 Months Ended
	Mar. 31, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventory consists of the following at:
	Inventory:	March 31, 2014		December 31, 2013
	Finished goods	$	217,667	$	360,607
	Work in progress		335,696		104,727
	Total Inventory	$	553,363	$	465,334

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property, Plant and Equipment [Abstract]	'
Property Plant And Equipment Useful Life [Table Text Block]	'
	Property and equipment and leasehold improvements are capitalized at cost and depreciated using the straight-line method (the Company used the double-declining balance method for property and equipment placed in service prior to January 2011) over estimated lives as follows:
	Equipment	5 - 10 years
	Vehicle	5 years
	Leasehold improvements	3 years
	Software	3 years
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consists of the following at:
			March 31, 2014		December 31, 2013
	Lab equipment		$	7,222,196	$	6,620,662
	Computer equipment			600,318		563,976
	Office equipment and vehicle			248,490		248,490
	Leasehold improvements			477,682		477,682
				8,548,686		7,910,810
	Accumulated depreciation			-5,223,933		-5,024,634
	Property and equipment, net		$	3,324,753	$	2,886,176

Longterm_Debt_Tables

Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Total debts outstanding are as follows:
				March 31, 2014		December 31, 2013
	1)	Note Payable to the WVDO		$	123,744	$	123,744
	2)	Note Payable to the WVEDA			147,306		147,306
	3)	Note Payable to the WVIJDC			145,078		145,078
	4)	Note Payable to the WVEDA			639,085		639,085
	5)	Note Payable to the WVIJDC			651,913		651,913
	6)	Note Payable to the WVJITB			290,000		290,000
	7)	Note Payable to the WVJITB			300,000		300,000
	8)	Note Payable to the WVHTCF			95,178		95,178
	9)	Note Payable to the WVEDA			170,932		170,932
	10)	Capital leases			412,278		71,077
		Total			2,975,514		2,634,313
		Less: current portion			-1,221,218		-1,054,053
		Long-term portion		$	1,754,296	$	1,580,260
Schedule of Maturities of Long-term Debt [Table Text Block]	'
	Future required minimum principal repayments over the next five years are as follows:
	Year Ending December 31:	Future Required Minimum Principal Repayments
	2014	$	1,104,334
	2015		390,360
	2016		360,217
	2017		345,839
	2018 & Thereafter		774,764
	Total	$	2,975,514

Common_Stock_Tables

Common Stock (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Schedule of Stock by Class [Table Text Block]	'
	The members of the Board of Directors are elected by the affirmative vote of the holders of a majority of the Company’s outstanding common stock.  Common stock issued are as follows:
					Price				Value of				Additional
		# Shares	Par		Per		Gross		Services		Par		Paid in
		Issued	Value		Share		Proceeds		Obtained		Value		Capital (1)
	Balance at December 31, 2013	65,442,735	$	0.0001		Various	$	53,694,771	$	829,132	$	6,545	$	54,517,358
	Issuance of stock (2)	25,000		0.0001	$	0.5		-		12,500		2		12,498
	Balance at March 31, 2014	65,467,735					$	53,694,771	$	841,632	$	6,547	$	54,529,856
	(1) Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.
	(2) Shares issued for services performed and did not contain an anti-dilution provision

Stock_Options_and_Stockbased_C1

Stock Options and Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Options and Stock Based Compensation [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of stock option activity is as follows:
								Weighted Average
					Weighted Average			Remaining
					Exercise			Contractual Life
			Shares		Price			(in years)
	Outstanding at December 31, 2013		5,082,750		$	1.11		7.02
	Granted		1,304,500		$	0.55
	Exercised		-			-
	Cancelled or expired		-87,500		$	1.5
	Outstanding at March 31, 2014		6,299,750		$	1.05		6.95
	Exercisable at December 31, 2013		4,005,583		$	1.2		6.52
	Exercisable at March 31, 2014		4,400,207		$	1.15		6.35
Summary of Options Outstanding and Options Exercisable [Table Text Block]	'
	The following table summarizes information about stock options at March 31, 2014:
	Options Outstanding									Options Exercisable
						Weighted Average		Weighted			Weighted
						Remaining Contractual		Average			Average
						Life (in years)		Exercise			Exercise
	Exercise Price			Outstanding				Price		Exercisable	Price
		$0.50		159,000						115,063
		$0.55		2,997,500						1,274,582
		$0.80		320,000						320,000
		$1.25		310,000						310,000
		$1.50		2,298,500						2,175,187
		$2.00		214,750						205,375
		$0.50 - $2.00		6,299,750		6.95		$	1.05	4,400,207	$	1.15
Schedule of Nonvested Share Activity [Table Text Block]	'
	The following table summarizes the activity of the Company’s stock options that have not vested:
			Shares		Weighted Average Grant-date Fair Value
	Nonvested at December 31, 2013		1,077,167		$	0.467
	Granted		1,122,751		$	0.205
	Forfeited		-87,500		$	1.027
	Vested		-212,875		$	0.566
	Nonvested at March 31, 2014		1,899,543		$	0.203
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense is as follows:
			Three Months Ended
			March 31, 2014			March 31, 2013
	Selling, general, and administrative expense		$	111,286		$	70,754
	Research and development expense			6,703			5,903
	Total stock-based compensation expense		$	117,989		$	76,657
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair value of the option grants was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions:
			Three Months Ended
			March 31, 2014		March 31, 2013
	Weighted average risk-free interest rate		2.35	%	0.14	%
	Volatility factor		73.56	%	24 - 73	%
	Weighted average expected life (in years)		7		7
	Dividend rate		0	%	0	%

Stock_Warrants_Tables

Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Warrants [Abstract]	'
Schedule Of Warrant Activity [Table Text Block]	'
							Weighted Average
					Weighted Average		Remaining
					Exercise		Contractual Life
			Shares		Price		(in years)
	Outstanding at December 31, 2013		52,705,614		$	1.3	2.58
	Granted		3,720,323		$	0.77	4.84
	Exercised		-			-
	Cancelled or expired		-			-
	Outstanding at March 31, 2014		56,425,937		$	1.28	2.69
Schedule Of Stock Warrant Outstanding [Table Text Block]	'
	The following table summarizes information about stock warrants at March 31, 2014:
	Warrants Outstanding
							Weighted
						Weighted Average	Average
						Remaining Contractual	Exercise
	Exercise Price			Outstanding		Life (in years)	Price
		$0.50		15,524,642
		$0.75		11,065,144
		$1.10		18,721,850
		$1.12		263,750
		$2.00		9,455,842
		$2.20		98,320
		$2.25		1,296,389
		$0.50 - $2.00		56,425,937		2.69	$	1.28

Lease_Commitments_Tables

Lease Commitments (Tables)	3 Months Ended
	Mar. 31, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	'
	Future required minimum principal repayments over the next five years are as follows:
	Year ending December 31:	Future required minimum lease payments
	2014	$	183,943
	2015	$	167,628
	2016	$	167,628
	2017	$	41,907

Description_of_Company_and_Nat1

Description of Company and Nature of Business (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Nature of Business [Line Items]	'	'
Entity Incorporation, State Country Name	'State of Delaware	'
Development Stage Enterprise, Deficit Accumulated During Development Stage	$61,124,486	$58,392,348

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		153 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Segment Reporting Information [Line Items]	'	'	'
Gross Revenue	$468,100	$481,615	$5,184,447
Molecular Information Services [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Gross Revenue	170,570	70,730	'
LAESI Instrument Platform [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Gross Revenue	178,000	296,694	'
Research Products [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Gross Revenue	95,342	114,191	'
Grants and Other Collaborations [Member]	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Gross Revenue	$24,188	$0	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
French government R&D credit	$399,971	$400,379
French payroll taxes receivable	36,900	34,899
Other receivables - current	436,871	435,278
Deposits	23,231	23,249
Other receivables - noncurrent	$23,231	$23,249

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Payables And Accruals [Line Items]	'	'
Accrued expenses	$411,688	$653,047
Accrued interest	75,738	39,911
Accrued warranties	97,500	81,250
Accrued payroll and benefits	275,374	286,979
Unearned revenue	2,200	7,980
Other payables and accrued expenses	$862,500	$1,069,167

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details 3) (Derivative Financial Instruments, Liabilities [Member])	3 Months Ended
	Mar. 31, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Fair Value Assumptions, Risk Free Rate	0.93%
Fair Value Assumptions, Expected Volatility Rate	80.23%
Probability of Future Capital Raises	100.00%
Maximum [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Fair Value Assumptions, Expected Life (Years)	'4 years 9 months
Minimum [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Fair Value Assumptions, Expected Life (Years)	'1 year

Summary_of_Significant_Account7

Summary of Significant Accounting Policies (Details 4) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	$557,665	$623,587	'
Derivative liabilities - warrant [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	93,159	64,788	0
Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Fair Value, Inputs, Level 1 [Member] | Derivative liabilities - warrant [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Fair Value, Inputs, Level 2 [Member] | Derivative liabilities - warrant [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	557,665	623,587	0
Fair Value, Inputs, Level 3 [Member] | Derivative liabilities - warrant [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	93,159	64,788	'
Derivative liabilities - common stock [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	464,506	558,799	0
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	0	0	'
Derivative liabilities - common stock [Member] | Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Derivative Liability	$464,506	$558,799	'

Summary_of_Significant_Account8

Summary of Significant Accounting Policies (Details 5) (USD $)

3 Months Ended

153 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Derivative liabilities - warrant [Member]

Derivative liabilities - warrant [Member]

Derivative liabilities - warrant [Member]

Derivative liabilities - warrant [Member]

Derivative liabilities - common stock [Member]

Derivative liabilities - common stock [Member]

Derivative liabilities - common stock [Member]

Derivative liabilities - common stock [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

$623,587

'

'

$623,587

$0

$64,788

$0

$93,159

$64,788

$558,799

$0

$464,506

$558,799

Issuance of warrants

30,476

25,000

905,292

0

45,685

0

45,685

'

'

0

0

'

'

Unrealized (gain) loss on derivative liabilities

'

'

'

-65,922

-379,986

28,371

-122,140

'

'

-94,293

-257,846

'

'

Recognition of derivative liabilities

'

'

'

0

957,888

0

141,243

'

'

0

816,645

'

'

Ending balance

$557,665

'

$557,665

$557,665

$623,587

$93,159

$64,788

$93,159

$64,788

$464,506

$558,799

$464,506

$558,799

Summary_of_Significant_Account9

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	60,826,000	56,711,000

Inventory_Details

Inventory (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory:	'	'
Finished goods	$217,667	$360,607
Work in progress	335,696	104,727
Total Inventory	$553,363	$465,334

Property_and_Equipment_Details

Property and Equipment (Details)	3 Months Ended
	Mar. 31, 2014
Computer Software, Intangible Asset [Member]	'
Property Plant And Equipment Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years
Equipment [Member] | Maximum [Member]	'
Property Plant And Equipment Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'10 years
Equipment [Member] | Minimum [Member]	'
Property Plant And Equipment Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years
Vehicles [Member]	'
Property Plant And Equipment Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'5 years
Leaseholds and Leasehold Improvements [Member]	'
Property Plant And Equipment Useful Life [Line Items]	'
Property, Plant and Equipment, Useful Life	'3 years

Property_and_Equipment_Details1

Property and Equipment (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Lab equipment	$7,222,196	$6,620,662
Computer equipment	600,318	563,976
Office equipment and vehicle	248,490	248,490
Leasehold improvements	477,682	477,682
Property, Plant and Equipment, Gross	8,548,686	7,910,810
Accumulated depreciation	-5,223,933	-5,024,634
Property and equipment, net	$3,324,753	$2,886,176

Property_and_Equipment_Details2

Property and Equipment (Details Textual) (USD $)	3 Months Ended		153 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation, Depletion and Amortization, Total	$206,046	$204,752	$5,449,428

Bank_Line_of_Credit_Details_Te

Bank Line of Credit (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Bank Line Of Credit [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity (in dollars)	$3,000,000	'
Line of Credit Facility, Interest Rate Description	'The interest rate is variable and is .75% plus prime with a minimum rate of 5.87%	'
Line of Credit Facility, Amount Outstanding (in dollars)	$3,000,000	$2,725,000
Line of Credit Facility, Interest Rate at Period End	5.87%	5.87%

Loans_Payable_to_Stockholders_

Loans Payable to Stockholders (Details Textual) (USD $)	1 Months Ended			3 Months Ended		3 Months Ended
	Aug. 06, 2013	Mar. 17, 2014	Mar. 05, 2014	Mar. 31, 2014	Mar. 26, 2014	Mar. 31, 2014
			Director [Member]	El Coronado Holdings Inc [Member]	Summit Resources Inc [Member]	Summit Resources Inc [Member]
						Subsequent Event [Member]
Loans Payable to Stockholders [Line Items]	'	'	'	'	'	'
Maximum Loan Amount Agreed	$600,000	'	'	'	'	'
Warrants Issued to Purchase of Common Stock, Shares	1,000,000	'	'	109,091	'	600,000
Warrants Issued to Purchase of Common Stock, Value	150,000	'	'	2,000,000	'	'
Warrant Exercise Price Per Share	$1.10	'	'	$0.80	'	'
Debt Conversion, Converted Instrument, Shares Issued	'	'	'	181,818	'	'
Fair Value of Warrants	134,117	'	'	'	'	'
Due to Related Parties, Current	'	175,000	30,000	'	400,000	200,000
Debt Instrument, Face Amount	'	'	'	175,000	'	600,000
Debt Instrument, Interest Rate, Effective Percentage	10.00%	'	'	10.00%	'	10.00%
Debt Instrument, Convertible, Conversion Price	'	'	'	'	'	$0.80
Outstanding Principal And Accrued Unpaid Interest	'	'	'	$100,000	'	'

Obligation_Related_to_the_Lett1

Obligation Related to the Letter of Credit (Details Textual) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Jun. 14, 2013

Mar. 31, 2014

Dec. 31, 2013

Aug. 06, 2013

Jun. 14, 2013

Mar. 06, 2013

Mar. 31, 2014

Mar. 31, 2013

Jun. 14, 2013

Jun. 14, 2013

Jun. 14, 2013

Mar. 31, 2013

Feb. 25, 2013

Warrant [Member]

Warrant [Member]

Mr Antoline [Member]

Mr Antoline [Member]

Mr Antoline [Member]

Mr Antoline [Member]

Laser Ablation Electrospray Lonization [Member]

Letter of Credit [Member]

Letter of Credit [Member]

Warrant [Member]

Mpr Associates [Member]

Mpr Associates [Member]

Obligation Related to Letter of Credit [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Obligation Related to the Letter of Credit

'

$69,827

$151,981

'

'

'

'

'

'

'

'

'

$600,000

Debt Instrument, Maturity Date

31-Dec-13

'

'

'

'

'

'

'

'

'

'

'

'

Draws on Letter of Credit

'

'

'

'

'

'

'

'

'

'

'

600,000

'

Class of Warrant or Right, Outstanding

'

'

'

'

'

1,100,000

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

'

'

'

10.00%

'

'

'

'

10.00%

'

'

'

'

Issuance of Warrants Value To Purchase Common Stock

'

'

'

'

250,000

'

'

'

'

'

'

'

'

Warrants Exercise Price

'

'

'

'

$1.10

'

'

'

'

'

'

'

'

Fair Value of Warrants

'

'

'

134,117

'

'

'

138,763

'

31,510

'

'

'

Discount to Reimbursement Agreement Balance

'

90,835

238,695

'

'

'

600,000

'

'

'

'

'

'

Accretion Expense

'

31,510

'

'

'

'

34,196

83,559

'

'

'

'

'

Discount to Addendum Balance

'

'

'

'

'

'

'

'

'

147,860

'

'

'

Proceeds from Short-term Debt, Total

'

'

'

'

'

'

'

'

'

'

$147,860

'

'

Longterm_Debt_Details

Long-term Debt (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	$2,975,514	$2,634,313
Less: current portion	-1,221,218	-1,054,053
Long-term portion	1,754,296	1,580,260
Note Payable To West Virginia Development Office [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	123,744	123,744
Note Payable To West Virginia Economic Development Authority, Series 1 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	147,306	147,306
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	145,078	145,078
Note Payable To West Virginia Economic Development Authority, Series 2 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	639,085	639,085
Note Payable To West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	651,913	651,913
Note Payable To West Virginia Jobs Investment Trust Board, Series 1 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	290,000	290,000
Note Payable To West Virginia Jobs Investment Trust Board, Series 2 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	300,000	300,000
Note Payable To West Virginia High Technology Consortium Foundation [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	95,178	95,178
Note Payable to West Virginia Economic Development Authority, Series 3 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt and Capital Lease Obligations, Total	170,932	170,932
Capital leases [Member]	'	'
Debt Instrument [Line Items]	'	'
Capital Lease Obligations	$412,278	$71,077

Longterm_Debt_Details_1

Long-term Debt (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Schedule of Capitalization, Long-term Debt [Line Items]	'	'
2014	$1,104,334	'
2015	390,360	'
2016	360,217	'
2017	345,839	'
2018 & Thereafter	774,764	'
Total	$2,975,514	$2,634,313

Longterm_Debt_Details_Textual

Long-term Debt (Details Textual) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

Jun. 14, 2013

Mar. 31, 2014

Mar. 31, 2007

Aug. 31, 2009

Aug. 31, 2009

Oct. 31, 2010

Dec. 31, 2010

Mar. 31, 2012

Dec. 13, 2013

Dec. 13, 2013

Apr. 30, 2012

31-May-12

Jun. 30, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Subsequent Event [Member]

Notes Payable to West Virginia Development Office [Member]

Notes Payable to West Virginia Economic Development Authority, Series 1 [Member]

Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 1 [Member]

Note Payable to West Virginia Economic Development Authority, Series 2 [Member]

Note Payable to West Virginia Infrastructure and Jobs Development Council, Series 2 [Member]

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 1 [Member]

Convertible Promissory Note Payable to West Virginia Jobs Investment Trust Board, Series 2 [Member]

Convertible Promissory Note Payable to West Virginia High Technology Consortium Foundation [Member]

Note Payable to West Virginia Economic Development Authority, Series 3 [Member]

Capital Leases [Member]

Capital Leases [Member]

Capital Leases [Member]

Capital Leases [Member]

Director [Member]

Due on March 15, 2014 [Member]

Due on June 15, 2014 [Member]

Subsequent Event [Member]

Maximum [Member]

Minimum [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Duration of Debt Instrument

'

'

'8 years

'10 years

'10 years

'10 years

'10 years

'18 months

'

'

'3 months

'30 months

'10 years

'

'

'

'

Long-term Debt, Gross (in dollars)

'

$540,835

$685,000

$242,631

$242,630

$900,000

$900,000

$290,000

'

'

$400,000

$200,000

$200,000

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

3.00%

4.00%

3.25%

3.26%

3.25%

6.00%

'

'

10.00%

8.00%

2.00%

'

'

'

'

Number of Debt Instrument Periodic Payments

'

'

'96 months

'120 months

'120 months

'120 months

'120 months

'

'

'

'

'25 months

'120 months

'

'

'

'

Debt Instrument, Periodic Payment

'

'

8,035

2,457

2,371

8,802

8,781

'

100,000

190,000

100,000

9,001

1,840

'

'

'

'

Debt Instrument, Periodic Payment, Principal

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

Debt Instrument, Maturity Date

31-Dec-13

'

30-Apr-15

31-Aug-19

31-Aug-19

31-Oct-20

31-Dec-20

30-Sep-13

'

'

30-Jun-12

30-Nov-14

30-Jun-22

'

'

'

'

Debt Instrument, Payment Terms

'

'

'

'

'

'

'

'monthly interest-only payments starting April 2012 through August 2013, then final interest and principal payments due September 2013

'

'

'monthly interest-only payments starting May 2012 through June 2012, then final interest and principal payments due July 2012

'

'

'

'

'

'

Debt Instrument, Collateral

'

'

'The note is secured by equipment

'The note is secured by 50% of equipment

'The note is secured by 50% of equipment

'The note is secured by equipment

'The note is secured by equipment

'

'

'

'

'The note is secured by 50% of equipment

'The note is secured by 50% of equipment

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

72,500

'

'

88,889

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

$2

'

'

$0.50

'

'

'

'

'

'

Pledged Assets, Not Separately Reported, Other

'

'

1,057,167

569,812

569,812

997,248

1,098,249

'

'

'

'

447,320

447,320

'

'

'

'

Duration of Lease

'

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

Imputed Interest Rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

2.90%

Lease Expiration Date

'

'

'

'

'

'

'

'

'

'

'

'

'

'April 2014 through May 2017

'

'

'

Capital Lease Obligation Collateral

'

'

'

'

'

'

'

'

'

'

'

'

'

'secured by equipment with an aggregate cost of $930,120

'secured by equipment costing $95,527

'

'

Debt Instrument, Face Amount

'

$59,165

'

'

'

'

'

'

'

'

$300,000

'

'

'

'

'

'

Common_Stock_Details

Common Stock (Details) (USD $)	3 Months Ended
	Mar. 31, 2014		Dec. 31, 2013
Class of Stock [Line Items]	'		'
Balance at December 31, 2013, Shares Issued (in shares)	65,442,735		'
Issuance of stock, Shares Issued (in shares)	25,000	[1]	'
Balance at March 31, 2014, Shares Issued (in shares)	65,467,735		'
Balance at December 31, 2013, Par Value (in dollars per share)	$0.00		$0.00
Issuance of stock, Par Value (in dollars per share)	$0.00	[1]	'
Balance at December 31, 2013, Price Per Share (in dollars per share)	'Various		'
Issuance of stock, Price Per Share (in dollars per share)	$0.50	[1]	'
Balance at December 31, 2013, Gross Proceeds (in dollars)	$53,694,771		'
Issuance of stock, Gross Proceeds (in dollars)	0	[1]	'
Balance at March 31, 2014, Gross Proceeds (in dollars)	53,694,771		'
Balance at December 31, 2013, Value of Services Obtained (in dollars)	829,132		'
Issuance of stock, Value of Services Obtained (in dollars)	12,500	[1]	'
Balance at March 31, 2014, Value of Services Obtained (in dollars)	841,632		'
Balance at December 31, 2013, Par Value (in dollars)	6,545		'
Issuance of stock, Par Value (in dollars)	2	[1]	'
Balance at March 31, 2014, Par Value (in dollars)	6,547		'
Balance at December 31, 2013, Additional Paid in Capital (in dollars)	54,517,358	[2]	'
Issuance of stock, Additional Paid in Capital (in dollars)	12,498	[1],[2]	'
Balance at March 31, 2014, Additional Paid in Capital (in dollars)	$54,529,856	[2]	'
[1]	Shares issued for services performed and did not contain an anti-dilution provision
[2]	Activity does not include issuance costs, deferred financing, warrants portion of convertible debentures and stock options.

Common_Stock_Details_Textual

Common Stock (Details Textual)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Class of Stock [Line Items]	'	'
Shares Authorized Total	210,000,000	'
Common Stock, Shares Authorized	200,000,000	200,000,000
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Voting Rights	'Common Stock par value of $.0001 per share with one vote in respect of each share held. Holders of common stock do not have cumulative voting rights.	'

Stock_Options_and_Stockbased_C2

Stock Options and Stock-based Compensation (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, Outstanding at December 31, 2013	5,082,750	'
Shares, Granted	1,304,500	'
Shares, Exercised	0	'
Shares, Cancelled or expired	-87,500	'
Shares, Outstanding at March 31, 2014	6,299,750	5,082,750
Shares Exercisable	4,400,207	4,005,583
Weighted Average Exercise Price, Outstanding at December 31, 2013	$1.11	'
Weighted Average Exercise Price, Granted	$0.55	'
Weighted Average Exercise Price, Exercised	$0	'
Weighted Average Exercise Price, Cancelled or expired	$1.50	'
Weighted Average Exercise Price, Outstanding at March 31, 2014	$1.05	$1.11
Weighted Average Exercise Price, Exercisable	$1.15	$1.20
Weighted Average Remaining Contractual Life (in years), Outstanding	'6 years 11 months 12 days	'7 years 7 days
Weighted Average Remaining Contractual Life (in years), Exercisable	'6 years 4 months 6 days	'6 years 6 months 7 days

Stock_Options_and_Stockbased_C3

Stock Options and Stock-based Compensation (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Options Outstanding, Exercise Price, Lower Limit (in dollars per share)	$0.50	'
Options Outstanding, Exercise Price, Upper Limit (in dollars per share)	$2	'
Options Outstanding (in shares)	6,299,750	5,082,750
Options Outstanding, Weighted Average Remaining Contractual Life (in years)	'6 years 11 months 12 days	'
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$1.05	$1.11
Option Outstanding, Exercisable	4,400,207	4,005,583
Weighted Average Exercise Price, Exercisable	$1.15	$1.20
Exercise Price 0.50 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$0.50	'
Options Outstanding (in shares)	159,000	'
Option Outstanding, Exercisable	115,063	'
Exercise Price 0.55 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$0.55	'
Options Outstanding (in shares)	2,997,500	'
Option Outstanding, Exercisable	1,274,582	'
Exercise Price 0.80 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$0.80	'
Options Outstanding (in shares)	320,000	'
Option Outstanding, Exercisable	320,000	'
Exercise Price 1.25 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$1.25	'
Options Outstanding (in shares)	310,000	'
Option Outstanding, Exercisable	310,000	'
Exercise Price 1.50 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$1.50	'
Options Outstanding (in shares)	2,298,500	'
Option Outstanding, Exercisable	2,175,187	'
Exercise Price 2.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Exercise Price (in dollars per share)	$2	'
Options Outstanding (in shares)	214,750	'
Option Outstanding, Exercisable	205,375	'

Stock_Options_and_Stockbased_C4

Stock Options and Stock-based Compensation (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, Nonvested, at December 31, 2013	1,077,167	'
Shares, Granted	1,122,751	'
Shares, Forfeited	-87,500	'
Shares, Vested	-212,875	'
Shares, Nonvested at March 31, 2014	1,899,543	'
Weighted Average Grant-date Fair Value, Nonvested, at December 31, 2013	$0.47	'
Weighted Average Grant-date Fair Value, Granted	$0.21	$0.11
Weighted Average Grant-date Fair Value, Forfeited	$1.03	'
Weighted Average Grant-date Fair Value, Vested	$0.57	'
Weighted Average Grant-date Fair Value, Nonvested at March 31, 2014	$0.20	'

Stock_Options_and_Stockbased_C5

Stock Options and Stock-based Compensation (Details 3) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$117,989	$76,657
Selling, General and Administrative Expenses [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	111,286	70,754
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$6,703	$5,903

Stock_Options_and_Stockbased_C6

Stock Options and Stock-based Compensation (Details 4)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Weighted average risk-free interest rate	2.35%	0.14%
Volatility factor	73.56%	'
Weighted average expected life (in years)	'7 years	'7 years
Dividend rate	0.00%	0.00%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility factor	'	73.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility factor	'	24.00%

Stock_Options_and_Stockbased_C7

Stock Options and Stock-based Compensation (Details Textual) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2002	Mar. 31, 2014
				Equity Incentive Plan 2002 [Member]	Equity Incentive Plan 2002 [Member]	Equity Incentive Plan 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	'	'	'	4,150,000	450,000	5,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$0	'	$0	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value	0	'	0	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award Estimated Fair Value of Stock Price (in dollars per share)	$0.50	'	$0.50	'	'	'
Shares Exercised (in shares)	0	0	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested and Expected to Vest Fair Value (in dollars)	296,831	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award Options Nonvested and Expected to Vest Weighted Average Expected Term	'2 years	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in dollars)	$117,989	$76,657	'	'	'	'
Weighted Average Grant-date Fair Value, Granted	$0.21	$0.11	'	'	'	'

Stock_Warrants_Details

Stock Warrants (Details) (Warrant [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Warrant [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, Outstanding at December 31, 2013	52,705,614	'
Shares, Granted	3,720,323	'
Shares, Exercised	0	'
Shares, Cancelled or expired	0	'
Shares, Outstanding at March 31, 2014	56,425,937	52,705,614
Weighted Average Exercise Price, Outstanding at December, 2013	$1.30	'
Weighted Average Exercise Price, Granted	$0.77	'
Weighted Average Exercise Price, Exercised	$0	'
Weighted Average Exercise Price, Cancelled or expired	$0	'
Weighted Average Exercise Price, Outstanding at March 31, 2014	$1.28	$1.30
Weighted Average Remaining Contractual Life (in years), Outstanding	'2 years 8 months 8 days	'2 years 6 months 29 days
Weighted Average Remaining Contractual Life (in years), Granted	'4 years 10 months 2 days	'

Stock_Warrants_Details_1

Stock Warrants (Details 1) (Warrant [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrants Outstanding (in shares)	56,425,937	52,705,614
Warrants Outstanding, Weighted Average Remaining Contractual Life (in years)	'2 years 8 months 8 days	'2 years 6 months 29 days
Warrant Outstanding, Weighted Average Exercise Price (in dollars per share)	$1.28	$1.30
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$2	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$0.50	'
Exercise Price 0.50	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$0.50	'
Warrants Outstanding (in shares)	15,524,642	'
Exercise Price 0.75	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$0.75	'
Warrants Outstanding (in shares)	11,065,144	'
Exercise Price 1.10	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$1.10	'
Warrants Outstanding (in shares)	18,721,850	'
Exercise Price 1.12	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$1.12	'
Warrants Outstanding (in shares)	263,750	'
Exercise Price 2.00	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$2	'
Warrants Outstanding (in shares)	9,455,842	'
Exercise Price 2.20	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$2.20	'
Warrants Outstanding (in shares)	98,320	'
Exercise Price 2.25	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Warrant Outstanding Exercise Price (in dollars per share)	$2.25	'
Warrants Outstanding (in shares)	1,296,389	'

Stock_Warrants_Details_Textual

Stock Warrants (Details Textual) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Stock Warrants [Line Items]	'	'
Placement Agent Services	$17,976	$537,137
Granting and Accruing Warrants	3,720,323	'
Interest Expense, Other	$65,706	'
Minimum [Member]	'	'
Stock Warrants [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Warrants Exercised in Period	'	$0.50
Maximum [Member]	'	'
Stock Warrants [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Warrants Exercised in Period	'	$1.10
Common Stock [Member]	'	'
Stock Warrants [Line Items]	'	'
Class of Warrant or Right Term of Warrants or Rights	'5 years	'
Class of Warrant or Right, Outstanding	56,425,937	'
Ability to Purchase Common Stock	'	7,592,400
Common Stock [Member] | Minimum [Member]	'	'
Stock Warrants [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Warrants Exercised in Period	$0.50	'
Common Stock [Member] | Maximum [Member]	'	'
Stock Warrants [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Warrants Exercised in Period	$2.25	'

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]	'	'
Operating Loss Carryforwards, Expiration Dates	'expire beginning 2021 for both federal and state purposes.	'
Operating Loss Carryforwards (in dollars)	$51,500,000	$50,000,000

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	Mar. 31, 2014
Lease Commitments [Line Items]	'
2014	$183,943
2015	167,628
2016	167,628
2017	$41,907

Lease_Commitments_Details_Text

Lease Commitments (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Lease Commitments [Line Items]	'	'
Description of Lessor Leasing Arrangements, Operating Leases	'The Company leases its USA facilities under operating leases beginning a) April 2012 through March 2017	'
Operating Lease, Leasing Term	'a month-to-month lease	'
Operating Leases, Rent Expense (in dollars)	$94,828	$109,498

Retirement_Plan_Details_Textua

Retirement Plan (Details Textual)	3 Months Ended
	Mar. 31, 2014
Retirement Plan [Line Items]	'
Description of Postemployment Benefits	'The Company provides a 401(k) Profit Sharing Plan (401(k) Plan) for elective deferrals whereby participants can defer up to 100% of their wages not to exceed a maximum dollar amount determined by the Federal Government each year.

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual)	3 Months Ended		12 Months Ended		12 Months Ended		3 Months Ended
	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014
	USD ($)	EUR (€)		USD ($)	Laboratories Mayoly Spindler [Member]	Laboratories Mayoly Spindler [Member]	George Washington University (GWU) [Member]	George Washington University (GWU) [Member]	Dynamic Manufacturing LLC [Member]	Bridger Photonics [Member]
					USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Malpractice Insurance, Maximum Coverage Per Incident (in dollars)	$5,000,000	'	'	'	'	'	'	'	'	'
Standard Product Warranty Description	'1	'1	'	'	'	'	'	'	'	'
Employee Service Share Based Compensation Options Issued	4,000	4,000	'	'	'	'	'	'	'	'
Agreement Description	'The agreement is cancellable with 90 days notice.	'The agreement is cancellable with 90 days notice.	'	'	'	'	'	'	'	'
Royalty Expense (in dollars)	'	1,000,000	'	'	'	'	'	'	'	'
Accounts Payable and Accrued Liabilities, Current (in dollars)	862,500	'	'	1,069,167	37,000	36,000	'	'	198,000	8,000
Commitments Outstanding (in dollars)	'	'	'	'	'	'	'	'	371,438	117,000
Development expense contribution	'	'	40.00%	'	60.00%	'	'	'	'	'
License Costs	'	'	'	'	'	'	25,000	'	'	'
Minimum License Diligence Resources Year Two	'	'	'	'	'	'	12,500	'	'	'
Minimum License Diligence Resources After Year Two	'	'	'	'	'	'	20,000	'	'	'
License and Maintenance Revenue	'	'	'	'	'	'	30,000	'	'	'
Royalties Percentage on Net Sales of Licensed Products	'	'	'	'	'	'	7.00%	'	'	'
Royalties Percentage on Combination Products for Combined Cumulative Net Sales	'	'	'	'	'	'	5.00%	'	'	'
Sales Revenue, Services, Net	'	'	'	'	'	'	50,000,000	'	'	'
Reduce Royalties Percentage After Net Sales of Licensed Products	'	'	'	'	'	'	6.00%	'	'	'
Reduce Royalties Percentage on Combination Products for Combined Cumulative After Net Sales	'	'	'	'	'	'	4.00%	'	'	'
Minimum Royalties Year One	'	'	'	'	'	'	1,500	'	'	'
Minimum Royalties Year Two	'	'	'	'	'	'	2,500	'	'	'
Minimum Royalties Year Three	'	'	'	'	'	'	3,000	'	'	'
Minimum Royalties Year After Three Year	'	'	'	'	'	'	6,000	'	'	'
Accrued Warranty Expense	97,500	'	'	81,250	'	'	'	'	'	'
Accrued Royalties	'	'	'	'	'	'	$45,800	$32,600	'	'

Option_Fee_Details_Textual

Option Fee (Details Textual) (USD $)	3 Months Ended		1 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Mar. 27, 2014	Mar. 31, 2014
			Laboratories Mayoly Spindler [Member]	BioPharma dbAzur, Inc [Member]
Option Fee [Line Items]	'	'	'	'
Non Refundable Fee	'	'	$300,000	'
Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent	$300,000	$0	'	$300,000
Option Fee Description	'Option Fee by the greater of $0.55 or the 20 day volume weighted average price	'	'	'

Evaluation_of_Subsequent_Event1

Evaluation of Subsequent Events (Details Textual) (USD $)

1 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

3 Months Ended

Aug. 06, 2013

Mar. 31, 2014

Mar. 17, 2014

Dec. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Jun. 14, 2013

Mar. 31, 2014

Mar. 31, 2014

Common Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Mr Antoline [Member]

Summit Resources Inc [Member]

BioPharma dbAzur, Inc [Member]

Director [Member]

Equity Incentive Plan 2013 [Member]

Affiliated Entity [Member]

Consultant [Member]

Promissory Notes [Member]

Convertible Debt [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Issued For Services

'

'

'

'

25,000

87,348

'

'

'

150,000

'

'

'

'

'

Proceeds from Related Party Debt

'

'

'

'

'

'

'

'

$20,000

'

'

'

'

'

'

Repayment of Obligation Related to Letter of Credit

'

'

'

'

'

'

90,835

'

'

'

'

'

'

'

'

Warrants To Purchase Common Stock

'

'

'

'

'

'

'

'

'

187,500

650,000

'

'

600,000

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

1.1

0.8

0.8

'

0.8

'

Warrant Expiration Term

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

Debt Instrument, Face Amount

'

'

'

'

'

'

59,165

'

'

'

'

'

'

'

100,000

Long-term Debt, Gross

'

'

'

'

'

'

540,835

'

'

'

'

426,000

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6.00%

Maximum Loan Amount Agreed

600,000

'

'

'

'

'

'

'

'

'

900,000

300,000

'

'

'

Debt Instrument, Interest Rate, Effective Percentage

10.00%

'

'

'

'

'

'

'

'

'

10.00%

'

10.00%

'

'

Warrants Issued to Purchase of Common Stock, Shares

1,000,000

'

'

'

'

'

'

'

'

'

900,000

109,091

'

'

'

Due to Related Parties, Current

'

'

175,000

'

'

'

'

'

'

'

650,000

'

'

'

'

Outstanding Principal And Accrued Unpaid Interest

'

'

'

'

'

'

'

'

'

'

'

100,000

'

'

'

Debt Conversion, Converted Instrument, Shares Issued

'

'

'

'

'

'

'

'

'

'

'

181,818

'

'

'

Increase In Convertible Notes issuable Offering Amount

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

'

'

Warrants Issued to Purchase of Common Stock, Value

$150,000

'

'

'

'

'

'

'

'

'

'

$2,000,000

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

'

1,122,751

'

'

'

1,042,500

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance

'

$1.05

'

$1.11

'

'

'

$0.55

'

'

'

'

'

'

'